WO2001036656A3 - A complex between hyaluronic acid and a biomolecule and its use - Google Patents
A complex between hyaluronic acid and a biomolecule and its use Download PDFInfo
- Publication number
- WO2001036656A3 WO2001036656A3 PCT/SE2000/002245 SE0002245W WO0136656A3 WO 2001036656 A3 WO2001036656 A3 WO 2001036656A3 SE 0002245 W SE0002245 W SE 0002245W WO 0136656 A3 WO0136656 A3 WO 0136656A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- complex
- hyaluronic acid
- biomolecule
- suited
- oral administration
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH] (Somatotropin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
Abstract
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00980185A EP1231926B1 (en) | 1999-11-15 | 2000-11-15 | Biomolecular complex formed between hyaluronic acid and a biomolecule, its method of manufacture and medical uses thereof |
DK00980185T DK1231926T3 (en) | 2000-11-15 | 2000-11-15 | Biomolecular complex formed by hyaluronic acid and a biomolecule, a process for its preparation and medical use thereof |
AU17481/01A AU1748101A (en) | 1999-11-15 | 2000-11-15 | New complex, and methods for its production and use |
CA002391647A CA2391647C (en) | 1999-11-15 | 2000-11-15 | Biomolecular complex formed between hyaluronic acid and a biomolecule |
DE60017783T DE60017783T2 (en) | 1999-11-15 | 2000-11-15 | BIOMOLECULAR COMPLEX MADE FROM HYALURONIC ACID AND A BIOMOLECULAR, METHOD OF MANUFACTURING THEREOF AND THEIR THERAPEUTIC USE |
AT00980185T ATE287720T1 (en) | 1999-11-15 | 2000-11-15 | BIOMOLECULAR COMPLEX FORMED FROM HYALURONIC ACID AND A BIOMOLECULE, PRODUCTION PROCESS THEREOF AND THEIR THERAPEUTIC USE |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9904121-2 | 1999-11-15 | ||
SE9904121A SE9904121D0 (en) | 1999-11-15 | 1999-11-15 | Hydrophobic biomolecular structure |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2001036656A2 WO2001036656A2 (en) | 2001-05-25 |
WO2001036656A3 true WO2001036656A3 (en) | 2001-11-15 |
WO2001036656B1 WO2001036656B1 (en) | 2002-02-28 |
Family
ID=20417718
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/SE2000/002245 WO2001036656A2 (en) | 1999-11-15 | 2000-11-15 | A complex between hyaluronic acid and a biomolecule and its use |
Country Status (9)
Country | Link |
---|---|
US (3) | US6448093B1 (en) |
EP (1) | EP1231926B1 (en) |
AT (1) | ATE287720T1 (en) |
AU (1) | AU1748101A (en) |
CA (1) | CA2391647C (en) |
DE (1) | DE60017783T2 (en) |
ES (1) | ES2236004T3 (en) |
SE (1) | SE9904121D0 (en) |
WO (1) | WO2001036656A2 (en) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4790911B2 (en) | 1999-01-13 | 2011-10-12 | アルケミア オンコロジー ピーティワイ リミテッド | Compositions and methods for enhancing the efficacy of drugs |
SE9904121D0 (en) * | 1999-11-15 | 1999-11-15 | Gustaf Jederstroem | Hydrophobic biomolecular structure |
US9066919B2 (en) | 2000-07-14 | 2015-06-30 | Alchemia Oncology Pty Limited | Hyaluronan as a chemo-sensitizer in the treatment of cancer |
AUPQ879500A0 (en) | 2000-07-14 | 2000-08-10 | Meditech Research Limited | Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease |
EP1480656A4 (en) * | 2002-02-15 | 2007-07-18 | Res Dev Foundation | Hyaluronic acid mediated adenoviral transduction |
WO2004100966A1 (en) | 2003-05-16 | 2004-11-25 | Bbk Bio Corporation | Preparation for preventing contact of pathogenic matter with living organism |
WO2007012133A1 (en) | 2005-07-27 | 2007-02-01 | Alchemia Oncology Pty Limited | Therapeutic protocols using hyaluronan |
AU2006289651B2 (en) * | 2005-09-07 | 2012-07-26 | Alchemia Oncology Pty Limited | Therapeutic compositions comprising hyaluronan and therapeutic antibodies as well as methods of treatment |
CN101743021A (en) * | 2007-05-07 | 2010-06-16 | 耶德斯特伦制药有限公司 | Stabilized suspension |
FR2925333B1 (en) * | 2007-12-19 | 2012-04-13 | Farid Bennis | PHARMACEUTICAL COMPOSITIONS COMPRISING AT LEAST ONE PROTEIN ACTIVE INGREDIENT PROTECTS DIGESTIVE ENZYMES |
RU2014120626A (en) * | 2014-05-22 | 2015-11-27 | Владимир Андреевич Сабецкий | INSULIN-CONTAINING MEDICINE OF LONG-TERM ACTION |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0014995A2 (en) * | 1979-02-21 | 1980-09-03 | Pharmacia Ab | Immunisation agent, a method of preparing the same and use thereof for producing antisera |
JPH02213A (en) * | 1987-10-19 | 1990-01-05 | Taiho Yakuhin Kogyo Kk | Long-acting physiologically active peptide preparation |
WO1991004058A2 (en) * | 1989-09-21 | 1991-04-04 | Norpharmco Inc. | Treatment of conditions and disease |
JPH0597694A (en) * | 1991-03-08 | 1993-04-20 | Denki Kagaku Kogyo Kk | Physiologically active peptide preparation |
WO1997037680A1 (en) * | 1996-04-05 | 1997-10-16 | The Board Of Trustees Of The University Of Illinois | Macromolecular complexes for drug delivery |
WO1998001160A2 (en) * | 1996-07-10 | 1998-01-15 | Danbiosyst Uk Limited | Compositions suitable for delivery of genes to epithelial cells |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4141973A (en) | 1975-10-17 | 1979-02-27 | Biotrics, Inc. | Ultrapure hyaluronic acid and the use thereof |
DE2907070A1 (en) * | 1979-02-23 | 1980-09-04 | Hoechst Ag | HETEROCYCLIC SPIRO-LINKED AMIDINE AND METHOD FOR THE PRODUCTION THEREOF |
CH666897A5 (en) * | 1983-10-11 | 1988-08-31 | Fidia Spa | NON-INFLAMMATORY HYALURONIC ACID FRACTIONS, PHARMACEUTICAL METHODS AND COMPOSITIONS. |
US5637566A (en) * | 1988-08-24 | 1997-06-10 | Southern Cross Biotech Pty. Ltd. | Method of improving carcass quality by administering growth hormone |
SE8804164A0 (en) | 1988-11-17 | 1990-05-18 | Per Prisell | Pharmaceutical preparation |
EP0522491B1 (en) | 1991-07-10 | 1998-11-18 | Takeda Chemical Industries, Ltd. | Compositions based on hyaluronic acid |
US5614212A (en) * | 1992-04-08 | 1997-03-25 | International Medical Associates, Inc. | Method of transdermally administering high molecular weight drugs with a polymer skin enhancer |
US5654006A (en) * | 1993-02-12 | 1997-08-05 | Mayo Foundation For Medical Education And Research | Condensed-phase microparticle composition and method |
WO1995016774A1 (en) * | 1993-12-17 | 1995-06-22 | Spinal Cord Society | Method for inducing dna synthesis in neurons |
US5844107A (en) * | 1994-03-23 | 1998-12-01 | Case Western Reserve University | Compacted nucleic acids and their delivery to cells |
EP0817620B1 (en) * | 1995-03-28 | 2002-01-30 | Fidia Advanced Biopolymers, S.R.L. | Nanospheres comprising a biocompatible polysaccharide |
NZ320006A (en) | 1995-10-23 | 2001-12-21 | Meditech Res Ltd | An adjuvant composition comprising hyaluronic acid for gene therapy either in the sense or antisense direction |
KR100236771B1 (en) * | 1997-04-01 | 2000-02-01 | 성재갑 | Hyaluronate microparticles for sustained release of drug |
JPH10158196A (en) * | 1996-05-16 | 1998-06-16 | Hisamitsu Pharmaceut Co Inc | Carrier for stabilization of nucleic acid |
SE9904121D0 (en) * | 1999-11-15 | 1999-11-15 | Gustaf Jederstroem | Hydrophobic biomolecular structure |
-
1999
- 1999-11-15 SE SE9904121A patent/SE9904121D0/en unknown
- 1999-12-06 US US09/455,472 patent/US6448093B1/en not_active Expired - Fee Related
-
2000
- 2000-11-15 AT AT00980185T patent/ATE287720T1/en active
- 2000-11-15 ES ES00980185T patent/ES2236004T3/en not_active Expired - Lifetime
- 2000-11-15 AU AU17481/01A patent/AU1748101A/en not_active Abandoned
- 2000-11-15 DE DE60017783T patent/DE60017783T2/en not_active Expired - Lifetime
- 2000-11-15 CA CA002391647A patent/CA2391647C/en not_active Expired - Fee Related
- 2000-11-15 WO PCT/SE2000/002245 patent/WO2001036656A2/en active IP Right Grant
- 2000-11-15 EP EP00980185A patent/EP1231926B1/en not_active Expired - Lifetime
-
2002
- 2002-07-02 US US10/186,732 patent/US6926910B2/en not_active Expired - Fee Related
-
2005
- 2005-07-13 US US11/179,673 patent/US7338931B2/en not_active Expired - Fee Related
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0014995A2 (en) * | 1979-02-21 | 1980-09-03 | Pharmacia Ab | Immunisation agent, a method of preparing the same and use thereof for producing antisera |
JPH02213A (en) * | 1987-10-19 | 1990-01-05 | Taiho Yakuhin Kogyo Kk | Long-acting physiologically active peptide preparation |
WO1991004058A2 (en) * | 1989-09-21 | 1991-04-04 | Norpharmco Inc. | Treatment of conditions and disease |
JPH0597694A (en) * | 1991-03-08 | 1993-04-20 | Denki Kagaku Kogyo Kk | Physiologically active peptide preparation |
WO1997037680A1 (en) * | 1996-04-05 | 1997-10-16 | The Board Of Trustees Of The University Of Illinois | Macromolecular complexes for drug delivery |
WO1998001160A2 (en) * | 1996-07-10 | 1998-01-15 | Danbiosyst Uk Limited | Compositions suitable for delivery of genes to epithelial cells |
Non-Patent Citations (3)
Title |
---|
DATABASE WPI Week 9007, Derwent World Patents Index; AN 1990-047916, XP002939890 * |
DATABASE WPI Week 9320, Derwent World Patents Index; AN 1993-164366, XP002939889 * |
VICTOR A. BLOOMFIELD: "DNA condensation", CURRENT OPINION IN STRUCTURAL BIOLOGY, vol. 1996, no. 6, 1996, pages 334 - 341, XP001009937 * |
Also Published As
Publication number | Publication date |
---|---|
EP1231926A2 (en) | 2002-08-21 |
CA2391647C (en) | 2008-03-11 |
EP1231926B1 (en) | 2005-01-26 |
US20070275069A9 (en) | 2007-11-29 |
WO2001036656A2 (en) | 2001-05-25 |
ATE287720T1 (en) | 2005-02-15 |
CA2391647A1 (en) | 2001-05-25 |
US7338931B2 (en) | 2008-03-04 |
US6448093B1 (en) | 2002-09-10 |
DE60017783D1 (en) | 2005-03-03 |
WO2001036656B1 (en) | 2002-02-28 |
US6926910B2 (en) | 2005-08-09 |
DE60017783T2 (en) | 2006-01-05 |
US20030096266A1 (en) | 2003-05-22 |
AU1748101A (en) | 2001-05-30 |
ES2236004T3 (en) | 2005-07-16 |
SE9904121D0 (en) | 1999-11-15 |
US20050255162A1 (en) | 2005-11-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2004110472A3 (en) | Fusion proteins | |
EP1329458A3 (en) | Peptides that lower blood glucose levels | |
WO2002074337A8 (en) | Hmgb1 protein inhibitors and/or antagonists for the treatment of vascular diseases | |
WO2002100390A3 (en) | Improved method of treating the syndrome of coronary heart disease risk factors in humans | |
WO2002048183A3 (en) | Compositions of peptide crystals | |
WO1999017755A3 (en) | Medicaments | |
WO2005055945A3 (en) | Mucoadhesive drug delivery devices and methods of making and using thereof | |
WO2004041153A3 (en) | Pharmaceutical composition including low dosages of desmopressin | |
IL147220A0 (en) | Indanyl-substituted benzole carbonamide, method for the production of the same, use thereof as a medicament and pharmaceutical preparations containing the same | |
EP1186293A3 (en) | Intermittent administration of a growth hormone secretagogue | |
WO2001036656A3 (en) | A complex between hyaluronic acid and a biomolecule and its use | |
YU68702A (en) | Novel lhrh-antagonists, production and use thereof as medicament | |
ZA200208761B (en) | Pharmaceutical form of administration for peptides, methods for its production and use. | |
AU2002212471A1 (en) | Peptides for use in the treatment of alzheimer's disease | |
HUP0401536A3 (en) | Peptides and/or proteins and use thereof for the production of a therapeutic and/or prophylactic medicament | |
AU2002309122A1 (en) | Compositions based on branched chain amino acids for improving the myocardial ventricular function in patients suffering from diabetes | |
BG104179A (en) | Phanquinon administration for the treatment of the alzheimer's disease | |
WO2003084979A3 (en) | Novel peptides and the application thereof in therapy | |
SE9902597D0 (en) | New use | |
WO2001068676A3 (en) | Lhrh-antagonists, production and use thereof as medicament | |
WO2002044384A3 (en) | T-cell epitope of the papillomavirus l1 and e7 protein and use thereof in diagnostics and therapy | |
MXPA02011533A (en) | NOVEL FORMULATIONS OF agr; 2, 4 DISULFOPHENYL N TERT BUTYLNITRONE. | |
CA2373252A1 (en) | Long lasting anti-angiogenic peptides | |
WO2000058466A3 (en) | Protease resistant flint analogs | |
WO2001040465A3 (en) | Compositions and methods for the treatment of immune related diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
AK | Designated states |
Kind code of ref document: B1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: B1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
B | Later publication of amended claims | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2391647 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000980185 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2000980185 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWG | Wipo information: grant in national office |
Ref document number: 2000980185 Country of ref document: EP |